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has an ocular hypotensive and neuroprotective
effect throughout 6 months of follow-up in a
glaucoma animal model†
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Intravitreal administration is widely used in ophthalmological practice to maintain therapeutic drug levels
near the neuroretina and because drug delivery systems are necessary to avoid reinjections and sight-
threatening side effects. However, currently there is no intravitreal treatment for glaucoma. The brimoni-
dine-LAPONITE® formulation was created with the aim of treating glaucoma for extended periods with a
single intravitreal injection. Glaucoma was induced by producing ocular hypertension in two rat cohorts:
[BRI-LAP] and [non-bri], with and without treatment, respectively. Eyes treated with brimonidine-
LAPONITE® showed lower ocular pressure levels up to week 8 (p < 0.001), functional neuroprotection
explored by scotopic and photopic negative response electroretinography (p = 0.042), and structural pro-
tection of the retina, retinal nerve fibre layer and ganglion cell layer (p = 0.038), especially on the
superior-inferior axis explored by optical coherence tomography, which was corroborated by a higher
retinal ganglion cell count (p = 0.040) using immunohistochemistry (Brn3a antibody) up to the end of the
study (week 24). Furthermore, delayed neuroprotection was detected in the contralateral eye.
Brimonidine was detected in treated rat eyes for up to 6 months. Brimonidine-LAPONITE® seems to be a
potential sustained-delivery intravitreal drug for glaucoma treatment.
1. Introduction
Glaucoma is the second-biggest cause of irreversible blind-
ness worldwide and the leading cause in developed
countries. According to the World Health Organization, it
affects over 61 million people. The main modifiable risk
factor is intraocular pressure (IOP) increase, which leads to
progressive retinal ganglion cell (RGC) death and subsequent
irreversible vision loss.1 However, RGC dysfunction and
death can also occur in ocular normotensive subjects.
Although not fully explored yet, several studies have shown
secondary degeneration of retinal cells due to the cytotoxic
environment (reactive oxygen species, nitric oxide, glutamate
or other free radicals) produced by surrounding affected
neurons.2
Brimonidine is a highly selective alpha-2 adrenergic pan-
agonist lipophilic drug.3 It has been used in ophthalmological
care to produce ocular hypotension since 1974.4 The 20–30%
reduction in IOP5 is due to its effect on alpha2A,C adrenergic
receptors in the ciliary epithelium,6,7 which inhibit aqueous
humour inflow and lead to an increase in uveoscleral
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outflow.8,9 The peak occurs within 2–3 hours and lasts until
10–14 hours after instillation.10 Therefore, to decrease IOP to
optimal therapeutic levels, topical eye drops must be adminis-
tered twice a day by the patient. This can have several disad-
vantages, such as therapeutic oversights, loss of drug efficacy
when crossing the anterior eye structures, and a remarkable
12.7% incidence of ocular and periocular allergic
reactions,11–13 or even intraocular inflammation.14 These draw-
backs worsen patient quality of life and decrease the compli-
ance rate, which lead to progression of the disease.15
Meanwhile, the neuroprotective effect of brimonidine has
been described by many research groups since the four criteria
used to evaluate the potential role of a neuroprotective agent
are widely proven:16 (1) brimonidine has targets (alfa-2A,B,C
adrenergic receptors for RGCs, glial cells and photoreceptors)
in the retina,7,17 (2) the neuroprotective effect was demon-
strated in cell and animal studies,18–20 mainly in the RGC body
and axons, but also in bipolar cells21 and photoreceptors,22 (3)
it reaches neuroprotection concentration on the posterior
segment where the drug interacts with retinal cells,23,24 and
finally (4) it showed neuroprotective characteristics in recent
clinical trials in patients with diabetes25 and age-related
macular degeneration.26
LAPONITE® Na+0.7 [(Si8Mg5.5Li0.3)O20(OH)4]
−0.7 is a biocom-
patible and biodegradable synthetic clay that in recent years
has been used in a wide range of biomedical and biomaterial
applications, particularly in nanomedicine, regenerative medi-
cine and tissue engineering.27 LAPONITE® is composed of
two-dimensional nanoscale disk-shaped crystals (0.92 nm
height, 25 nm diameter, 2.65 × 103 g cm−3 density) comprising
an octahedral magnesia sheet sandwiched between two tetra-
hedral silica sheets.28 When dispersed in aqueous media, a
three-dimensional house-of-cards structure is formed. Sodium
ions are released, leading to a weak negative-charge surface
and further water absorption, resulting in an increase in the
clay’s volume.29,30 It forms a clear colloidal dispersion with
thixotropic, viscoelastic and transparent gel characteristics,
suitable for administration by injection.28 Since it is able to
interact with other molecules by ion-exchange, van de Waals
forces, hydrogen bonding, cation/water bridging, protonation
or ligand exchange, LAPONITE® is even able to bring into
solution compounds that are water insoluble.31 It can act as a
carrier for several drugs,32 and can also release drugs in a con-
trolled manner depending on surrounding conditions such as
pH or temperature.33–35 Degradation of LAPONITE® releases
products that have, by themselves, biological roles; Reffitt
et al., showed an increase in collagen type I synthesis because
of orthosilicic acid [Si(OH)4];
36 magnesium ions may also
trigger cell responses, stabilize polyphosphate compounds in
cells such as adenosine triphosphate (ATP), or be involved in
enzymatic activity and signalling processes; sodium cations
interfere with the generation of nerve impulses and the hydro-
electrolyte balance, and lithium affects the behaviour of
neurons.37,38 Previous animal studies demonstrated
LAPONITE®’s safety39 and analysed the pharmacokinetics and
pharmacodynamics up to 24 weeks of intravitreal injection of
dexamethasone-LAPONITE® formulation in the vitreous
humour of rabbit eyes.40
Intravitreal injection is the gold standard therapeutic
option for posterior segment pathologies such as age-related
macular degeneration, diabetic retinopathy or vascular occlu-
sions. It has long been used in ophthalmological treatment41
because it maintains therapeutic drug levels at the target site
while avoiding ocular barriers.42 Thus, repeated ocular injec-
tions are needed, threatening complications such as IOP
elevation, intraocular inflammation, cataract formation,
retinal detachment or even endophthalmitis, with a 0.02%
incidence per injection in the latter.43–45 Minimally invasive
sustained drug delivery maintains therapeutic concentration
for prolonged periods, enhancing the half-life and bio-
availability of the drug and preventing the need for frequent
administration.46
There is currently no intravitreal treatment focused on
control of glaucomatous neuropathy that simultaneously
decreases the IOP and prevents neuroretinal damage.
To our knowledge, this is the first study demonstrating that
a sustained-release brimonidine-LAPONITE® formulation,
administered in a single intravitreal injection, exerts a func-
tional and structural ocular hypotensive and neuroprotective
effect lasting at least 6 months in a glaucoma animal model.
2. Materials and methods
Chemicals and reagents
Brimonidine and 2-bromoquinoxaline were obtained from
Sigma-Aldrich (Madrid, Spain). LAPONITE®-RD (LAP) (surface
density 370 m2 g−1, bulk density 1000 kg m−3, chemical com-
position: SiO2 59.5%, MgO 27.5%, Li2O 0.8%, Na2O 2.8%) was
obtained from BYK Additives (Widnes, Cheshire, UK).
Balanced 0.9% salt solution (9 mg ml−1 NaCl) (BSS) was
obtained from Fresenius Kabi (Barcelona, Spain). HPLC-grade
ethanol, acetonitrile, methanol, ammonium formate, formic
acid, ammonia and phosphoric acid (85% w/w) were obtained
from Scharlab (Barcelona, Spain). Oasis MCX Prime 96-well
µElution plates were obtained from Waters Chromatography
(Barcelona, Spain).
Brimonidine-LAPONITE® formulation
Brimonidine (BRI) was loaded on LAPONITE® (LAP) following
the previously described methodology for dexamethasone.40,47
Thus, BRI/LAP was prepared by adding LAP (100 mg) to a solu-
tion of brimonidine in ethanol (10 mg per 10 ml), stirring at r.
t. with solvent evaporation under vacuum to get a good dis-
persion of brimonidine on the surface. The BRI/LAP powder
was stored at −30 °C in tightly capped single-use vials that
were gamma-ray sterilized.
Drug load on the LAP was determined using the ultra-high-
pressure liquid chromatography mass spectrometry
(UHPLC-MS) method (see below). Sample powder (5 mg) was
extracted in 5 ml of acetonitrile/ethanol (1/1 v/v). After 1 h of
stirring, the sample was centrifuged at 3000 rpm for 10 min at
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r.t. and the supernatant was analysed, yielding a total load of
8.98 mg per 100 mg of solid (98.8% of the initial amount).
Immediately before injection, the brimonidine/LAP powder
was suspended in BSS (10 mg ml−1) and gently vortexed for
10 min to yield a yellow colloidal dispersion.
Sample processing for pharmacokinetic determination
Each rat eye was cut with dissecting scissors, 1 ml of 5%
formic acid solution in acetonitrile was added and the mixture
was sonicated at 45 W power for 10 min with a Hielscher
UP50H ultrasound processor. Next, 1 ml of 200 mM
ammonium formate in 4% phosphoric acid, and 100 µλ of
50 ppm 2-bromoquinoxaline internal standard (IS) in 0.1%
formic acid in acetonitrile were added to the purée and the
mixture was sonicated for 10 additional minutes. The sample
was then centrifuged at 3000 rpm for 10 min. The supernatant
was collected and cleaned up by solid phase extraction (SPE)
in an Oasis MCX µElution plate. Thus, the supernatant was
passed through the adsorbent under vacuum, and the
adsorbed sample was rinsed with 600 µl of methanol. The
adsorbed BRI and IS were eluted from the plate with 500 µl of
5% ammonia solution in methanol. The collected extract was
evaporated under vacuum and dissolved in 200 µl of 0.1%
formic acid in acetonitrile. The solution was analysed by
UHPLC-MS. Recovery of the analyte was determined on spiked
samples of rat eye at three concentration levels (low, medium
and high) and was found to be between 92% (lowest concen-
tration level) and 98% (highest concentration level).
Analytical method
Samples were analysed using a Waters Acquity UPLC instru-
ment coupled to a Waters Acquity QDa mass spectrometer.
The chromatographic separation was achieved using a Waters
Cortecs T3 column (1.6 µm, 2.1 × 75 mm) at 30 °C. The mobile
phase comprised a mixture of 0.1% formic acid in water
(solvent A) and 0.1% formic acid in acetonitrile (solvent B).
Samples (10 µl) were eluted in gradient mode (t = 0 min, 75%
A; t = 3 min, 50% A, t = 4 min, 75% A) at a flow rate of 0.5 ml
min−1.
The MS instrument was operated in electrospray ionization
(ESI) positive mode. Full scan mode (150–500 Da) was used to
identify the analytes (m/z = 292 (100%) and 294 for brimoni-
dine and m/z = 209 (100%) and 211 (92.8%) for 2-bromoqui-
noxaline as the IS). Quantization was carried out in single ion
monitoring (SIM) mode (m/z = 292 and 209 for brimonidine
and 2-bromoquinoxaline, respectively).
The method was validated according to the ICH guidelines.
Selectivity was assessed by analyzing blank samples from non-
treated rat eyes, and no interferences were found. Calibration
curves for brimonidine were constructed in the range
1–0.025 µg mL−1 by plotting the brimonidine/IS peak area
ratio vs brimonidine nominal concentration. A weighted (1/X2)
linear regression model was applied to fit the data (r2 > 0.999).
The measured concentration of the standard samples was
found to be within 10% of the nominal concentration,
showing the accuracy of the method. The limit of detection
(LOD) was found to be 0.005 µg mL−1, calculated by the stan-
dard error of the intercept method. The LOD was assessed
with a sample of nominal concentration obtained by the
method of signal-to-noise ratio of at least 10. The limit of
quantization (LOQ) was determined by the standard error of
the intercept method and was found to be 0.017 µg mL−1.
Animals
The study was carried out on 91 4 week old Long–Evans rats
(40% males, 60% females) weighing from 50–100 grams at the
beginning of the study. The animals were housed in standard
cages with water and food ad libitum in rooms kept at a con-
trolled temperature (22 °C) and relative humidity (55%) with
12-hour dark/light cycles. The work with animals was carried
out in the experimental surgery service department of the
Aragon Biomedical Research Centre (CIBA). The experiment
was previously approved by the Ethics Committee for Animal
Research (PI34/17) and was carried out in strict accordance
with the Association for Research in Vision and
Ophthalmology’s Statement for the Use of Animals.
Ocular hypertension (OHT) induction and drug injection
procedure
The animals were divided in two cohorts: [non-bri] and
[BRI-LAP]. The [non-bri] cohort comprised 31 rats. In this
cohort, OHT was induced in the right eye (RE) and the left eye
(LE) was untreated and served as the control eye. The
[BRI-LAP] cohort comprised 60 rats. In this cohort, OHT was
induced in both eyes but the RE received an intravitreal injec-
tion with the brimonidine-LAPONITE® (Bri-Lap) formulation.
The RE served as the treated hypertensive eye and the LE
served as the hypertensive control eye.
Ocular hypertension was generated using the model
described by Morrison et al. by means of sclerosis of episcleral
veins48 with a hypertonic 1.8 M solution in topical eye drops
(Anestesico doble Colircusi®, Alcon Cusí® SA, Barcelona, Spain)
and general anaesthesia by intraperitoneal (IP) injection
(60 mg kg−1 of ketamine + 0.25 mg kg−1 of dexmedetomidine).
To maintain OHT, animals in both cohorts were re-injected
every two weeks if IOP measurements were less than
20 mmHg. At the baseline, the [BRI-LAP] cohort received
3 µl 49 of the Bri-Lap formulation (10 mg Bri-Lap per ml;
amount of brimonidine injected: 2.69 µg, 0.13 mg ml−1 of vitr-
eous humour, considering a rat vitreous volume of 20 µl 50).
Determination of this concentration, applying the corres-
ponding scale correction, was based on the doses given by
other authors to rats (8.8 mg of brimonidine in nanoparticles,
0.44 mg ml−1 of vitreous, induces neuroprotection),51 mice
(1.07 mg of Bri-tartrate in nanosponges, 0.14 mg Bri per ml of
vitreous, induces ocular hypopressure)52 and rabbits (lower
dose of 0.45 mg of Bri-tartrate in microspheres, 0.20 mg ml−1
of vitreous, induces ocular hypopressure).53 REs were intravi-
treally injected using a Hamilton® syringe (measured in µl)
and a glass micropipette, which allowed visualization of the
yellowish formulation being administered. After intervention,
animals were left to recover at a temperature controlled by
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warm pads, with a 2.5% enriched oxygen atmosphere and
lubricant antibiotic ointment on the eyes.
Clinical, functional and structural in vivo ophthalmological
examination
Clinical ophthalmological signs such as redness, scarring, infec-
tion or intraocular inflammation were evaluated weekly.
Measurements of intraocular pressure were also recorded with the
Tonolab® rebound tonometer. The IOP value was the average of
three consecutive measurements resulting from the average of 6
rebounds. For this purpose, rats were sedated for less than three
minutes with a mixture of 3% sevoflurane gas and 1.5% oxygen to
avoid the potential effect of gas anaesthesia, as recommended.54
Neuroretinal structure functionality was studied using electrore-
tinography (ERG) (Roland consult® RETIanimal ERG, Germany)
with flash scotopic ERG and photopic negative response (PhNR)
protocols at the baseline and 8, 12 and 24 weeks. To test flash sco-
topic ERG, animals were dark-adapted for 12 hours and anaesthe-
tized with IP and topical anaesthesia. Their eyes were fully dilated
with mydriatic eye drops (tropicamide 10 mg ml−1, phenylephrine
100 mg ml−1, Alcon Cusí® SA, Barcelona, Spain) and their cornea
was lubricated (hypromellose 2%). Corneal electrodes served as
active electrodes, reference electrodes were placed subcutaneously
on both sides, and the ground electrode was placed near the tail.
Electrode impedance was accepted if there was a difference of <2
kΩ between electrodes. Both eyes were simultaneously tested using
a Ganzfeld Q450 SC sphere with white LED flashes for stimuli and
seven steps were performed with increasing luminance intensity
and intervals (step 1: 0.0003 cds m−2, 0.2 Hz s−1; step 2: 0.003 cds
m−2, 0.125 Hz s−1; step 3: 0.03 cds m−2, 8.929 Hz s−1; step 4: 0.03
cds m−2, 0.111 Hz s−1; step 5: 0.3 cds m−2, 0.077 Hz s−1; step 6: 3.0
cds m−2, 0.067 Hz s−1; and step 7: 3.0 cds m−2, 29.412 Hz s−1).55
The PhNR protocol was performed after light adaptation to a blue
background (470 nm, 25 cds m−2) and red LED flashes (625nm,
0.30 cds m−2) were used as stimuli. Latency (in milliseconds) and
amplitude (in microvolts) were studied in a, b and PhNR waves.
Neuroretinal structures were studied using optical coherence
tomography (OCT Spectralis, Heidelberg® Engineering, Germany)
at the baseline, 3 days and at 2, 4, 6, 8, 12, 24 weeks after the Bri-
Lap injection. Protocols such as retina posterior pole (R), retinal
nerve fibre layer (RNFL) and ganglion cell layer (GCL) with auto-
matic segmentation were evaluated. These protocols analysed an
area of 1, 2 and 3 mm around the centre of the optic disc by
means of 61 b-scans, and subsequent follow-up examinations were
performed at this same location using the eye-tracking software
and follow-up application. The vitreous was also visualized using
the en face vitreous protocol. For the scans, rats were IP anaesthe-
tized (as mentioned above) and a flat contact lens was adapted to
their cornea to obtain high-quality images.
A masked trained technician discarded biased examin-
ations or corrected them manually if the algorithm had
obviously erred.
Immunohistochemistry
Under general anaesthesia, animals were euthanized with an
intracardiac injection of sodium thiopental (25 mg ml−1). Eyes
were immediately enucleated, fixed in neutral-buffered forma-
lin (10%) and embedded in paraffin. A total of 44 eyes belong-
ing to 22 rats from the [BRI-LAP] cohort were analysed
(22 hypertensive REs injected with Bri-Lap and 22 control
hypertensive LEs). Embedded eyes were trimmed to reach the
optic nerve head. Next, 5 µm sections were deparaffined, rehy-
drated and washed in 10% H2O2 for 5 minutes (quenching)
before incubation of the following primary antibodies at 4 °C
overnight: mouse anti-Brn3a (Santa Cruz Biotechnology, Inc.,
Heidelberg, Germany) at 1 : 50 dilution; and rabbit anti-glial
fibrillary acidic protein (GFAP) (DAKO, Bath, United Kingdom)
at 1 : 1000 dilution. After that, sections were incubated for
90 minutes at room temperature with specific secondary anti-
bodies: biotinylated horse anti-mouse at 1 : 50 dilution and
biotinylated goat anti-rabbit at 1 : 100 dilution (Vector
Laboratories, Burlingame, CA, USA). They were then incubated
with ABC-HRP (Thermo Fisher Scientific, Waltham
Massachusetts, USA) at 1 : 50 dilution for 90 minutes at room
temperature. The sections were washed in phosphate-buffered
saline before and after every incubation. Finally, the sections
were stained with diaminobenzidine (DAB) for 3 minutes
and counterstained with Harris haematoxylin (Sigma-
Aldrich Corp., St Louis, MO, USA) for 20 minutes at room
temperature. Procedural immunohistochemistry controls were
performed by omission of the primary antibody in a sequential
tissue section. Eye sections stained with haematoxylin/eosin
were also used to analyse the general morphology of the
retina.
Retinal ganglion cell count
Retinal ganglion cells were counted in radial sections of the
retina along 2 mm of a linear region of the ganglion cell layer
and corresponding to four areas, two on each side of the optic
nerve head. Images were analysed by an operator blinded to
treatment groups.
Statistical analysis
This was a longitudinal and interventionist study. All data were
recorded in an Excel database, and statistical analysis was per-
formed using SPSS software version 20.0 (SPSS Inc., Chicago,
IL). The Kolmogorov–Smirnov test was used to assess sample
distribution. Given the non-parametric distribution of most of
the data, the differences between the cohorts were evaluated
using the Mann–Whitney U test and the changes recorded in
each eye over the 24-week study period were compared using a
paired Wilcoxon test. All values were expressed as means ±
standard deviation. Values of p < 0.05 were considered to indi-
cate statistical significance. To avoid a high false-positive rate,
the Bonferroni correction for multiple comparisons was calcu-
lated. The level of significance for each variable was estab-
lished based on Bonferroni calculations.
Statistical analysis of the number of ganglion cells was con-
ducted in R (v. 3.6.0) using a paired t-test. The results are
shown as mean ± standard error of the mean (SEM). Values of
p < 0.05 were considered to indicate statistical significance.
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Intraocular pressure and clinical signs
In the [non-bri] cohort, an IOP increase of >20 mmHg was
found in the RE between weeks 1 and 10, peaking at week 7
(29.92 ± 7.39 mmHg). Between week 11 and the end of the
study (week 24) IOP remained stable at 17.38 ± 2.87 to 23.66 ±
5.45 mmHg (Fig. 1a).
In the [BRI-LAP] cohort, REs showed normotensive levels
(IOP < 20 mmHg) until week 3, after which IOP increased,
ranging between 17.36 ± 4.10 and 23.99 ± 4.04 mmHg until the
end of the study. LEs also showed progressive increases in IOP
throughout follow-up. REs, however, showed statistically sig-
nificant higher levels of IOP than LEs (Fig. 1b).
When REs from the [non-bri] and [BRI-LAP] cohorts were
compared, the eyes treated with Bri-Lap always exhibited stat-
istically lower IOP levels from weeks 1 to 10, and even
Bonferroni correction for multiple comparisons (marked with
**) was exceeded from weeks 1 to 8 (p < 0.001). However, this
trend inverted from week 12 and no statistical differences were
found after that (Fig. 1a).
The percentage of eyes with OHT (>20 mmHg) in both
cohorts was studied and analysis revealed a lower percentage
of hypertensive eyes when treated with Bri-Lap up to week 8.
This was especially remarkable during the first month (0% vs.
72% at week 1, 4.8% vs. 88% at week 2, and 28.1% vs. 91.7% at
week 4, respectively) both in the injected RE but also in the
untreated LE. Nevertheless, a higher percentage of hyperten-
sive eyes treated with Bri-Lap intravitreal formulation from the
[BRI-LAP] cohort, as compared with the LEs used as hyperten-
sive controls, was found throughout the study (Fig. 1c).
There were no cases of allergic reaction, infection, intra-
ocular inflammation or retinal detachment. Two animals
developed cataracts during the episcleral vein sclerosis pro-
cedure, though these reverted spontaneously in the sub-
sequent weeks.56 One case of cataract formation after the intra-
vitreal injection developed, probably due to surgical issues as
rats have thick lenses. This animal was thus only used for
histological studies. As a remarkable adverse event, fifteen
early and unexpected animal deaths occurred without any
obvious cause: four rats died at week 2, four rats died at week
4, six rats died at week 8 and one rat died at week 12.
Fig. 1 Intraocular pressure curves. (a) Right eye comparison between the [non-bri] cohort (rats with ocular hypertension in the right eye) and the
[BRI-LAP] cohort (rats with ocular hypertension in both eyes and an intravitreal injection of brimonidine-LAPONITE® formulation in the right eye).
(b) Comparison between right and left eyes in the [BRI-LAP] cohort. (c) Percentage of ocular hypertensive eyes (>20 mmHg) in the [non-bri] cohort
and the [BRI-LAP] cohort during follow-up. Abbreviations: IOP: intraocular pressure; RE: right eye; LE: left eye; w: week; d: day; *p < 0.05: statistical
differences, **p < 0.001: statistical differences with Bonferroni’s correction. REs from the [non-bri] cohort received an ocular hypertensive injection
by sclerosing the episcleral veins. LEs from the [non-bri] cohort did not receive any treatment. REs from the [BRI-LAP] cohort received an ocular
hypertensive injection by sclerosing the episcleral veins plus an intravitreal injection with brimonidine-LAPONITE® formulation. LEs from the
[BRI-LAP] cohort received an ocular hypertensive injection by sclerosing the episcleral veins.
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REs from the [non-bri] cohort showed a decreasing tendency
in amplitude in a (13.25 ± 16.78 vs. 67.53 ± 138.31 μV), b (44.64
± 28.20 vs. 56.54 ± 53.34 μV) and PhNR (18.68 ± 24.77 vs. 25.52
± 26.79 μV) waves when explored using the PhNR protocol at
week 24 with respect to week 12, although no statistical differ-
ences were found.
The [BRI-LAP] cohort did not exhibit statistical differences
in latency between REs and LEs when explored using the sco-
topic flash ERG protocol, but statistically significant higher
amplitudes in a and b waves were found in the REs injected
with Bri-Lap formulation as compared with LEs, mainly with
lower intensity stimulus, at 8, 12 and 24 weeks. Similar results
were obtained with the PhNR protocol, in which no statistical
differences in latency were found between eyes, although a ten-
dency to maintain this value was observed over 24 weeks.
Statistically significant higher amplitudes in REs vs. LEs were
also obtained in a, b and PhNR waves at 8, 12 and 24 weeks.
Furthermore, a progressively increasing trend in PhNR wave
amplitude was found in REs from weeks 8 to 12 (Fig. 2a and
b).
When REs from the [non-bri] and [BRI-LAP] cohorts were
compared, no statistically significant differences in latency
were found using any protocol. The scotopic ERG test at week
24 showed worse statistically significant results in the ampli-
tude and latency parameters in the [BRI-LAP] cohort, but the
PhNR protocol revealed statistically significant higher ampli-
tudes in the PhNR wave at week 12 and in the a and PhNR
waves at week 24 in eyes treated with the Bri-Lap formulation
(Fig. 2c and d).
Optical coherence tomography
In the [non-bri] cohort, REs showed a progressive loss in R,
RNFL and GCL thickness measured by OCT over 24 weeks of
follow-up.
In the [BRI-LAP] cohort, REs showed a trend towards
greater R thickness and lower percentage loss (mainly in the
inner sectors at early stages; p < 0.05) when compared with
untreated contralateral hypertensive LEs (Fig. 3a). Higher
RNFL thickness and, consequently, lower percentage loss were
found in REs over follow-up with statistically significant differ-
ences in the early stages (Fig. 3a). A striking increase in thick-
ness in most sectors was also found at day 3. When analysing
the GCL protocol, LEs exhibited greater thickness (p < 0.05) in
outer sectors in the early stages (outer nasal and outer tem-
poral sectors at weeks 2 and 4, respectively). However, a lower
percentage loss trend was observed in REs throughout the rest
of the follow-up (ESI Table 1†).
With the aim of finding out the total effect exerted by the
Bri-Lap formulation, REs from the [non-bri] and [BRI-LAP]
cohorts were compared. Retina scans from the [BRI-LAP]
cohort showed a tendency towards greater thickness in the
early stages (statistically significant sectors are detailed in
Fig. 3b). Analysing the RNFL protocol, a tendency to greater
thickness in eyes injected with Bri-Lap formulation was
observed from early/intermediate stages through to the end of
the study, and the glaucomatous superior/inferior axis showed
higher statistical significance (Fig. 3b). According to GCL
examinations in the [BRI-LAP] cohort, all sectors (except the
temporal sector) exhibited greater thicknesses with statistical
significance in the superior/inferior axis at earlier stages
(Fig. 3b); at the end of the study (week 24) every single sector
from the group injected with Bri-Lap formulation had greater
thicknesses, reaching statistically significant differences in the
inner inferior and outer temporal sectors (ESI Table 2†).
To evaluate if the Bri-Lap formulation could exert an effect
on the contralateral eye, LEs from the [non-bri] cohort (control
eye without any treatment, but with contralateral OHT eye) vs.
LEs from the [BRI-LAP] cohort (OHT eye without treatment but
with Bri-Lap injection in the contralateral OHT eye) were com-
pared. No statistical differences were found in most sectors at
any of the stages analysed, except at week 24, when greater
RNFL thickness was measured in the [BRI-LAP] cohort
explored using the RNFL protocol in the nasal superior sector
(18.57 ± 6.24 vs. 34.60 ± 10.55 μm, p = 0.023), and in GCL thick-
ness explored using the GCL protocol in total volume (0.14 ±
0.01 vs. 0.15 ± 0.01 μm, p = 0.030) and in the inner inferior
sector (21.71 ± 1.60 vs. 26.20 ± 1.09 μm, p = 0.004). LEs from
both cohorts were >20 mmHg at week 24. However, by that
stage LEs from the [BRI-LAP] cohort had statistically higher
axonal and ganglion thickness than LEs from the [non-bri]
cohort.
Images from vitreous scans showed hyperreflective aggre-
gates of Bri-Lap formulation dispersed in the vitreous body as
floaters, with a tendency to move to the vitreoretinal interface.
A progressive decrease in the number and size of Bri-Lap
aggregates was also detected over time (ESI Video 1†).
Immunohistochemistry
In experimental glaucoma, accurate measures of the number
of RGCs are essential to evaluating the efficacy of novel thera-
peutic agents.57 However, because there are around 30
different types of RGCs with different morphologies, gene
expression and physiological properties,58 it is necessary in
experimental glaucoma to use a marker that identifies all the
different types of RGCs. In this study, we have used an anti-
body against transcription factor Brn3a that is considered the
most reliable pan-marker of RGCs in retinal sections.59
As expected,60 simple visual examination revealed that the
central areas of the retina showed greater density of RGCs
marked with anti-Brn3a than the peripheral areas (Fig. 4a).
Furthermore, the count of positive Brn3a cells along 2 mm of
the retina showed that the mean number of RGCs was signifi-
cantly higher in hypertensive eyes injected with the Bri-Lap for-
mulation than in untreated contralateral hypertensive eyes
(REs 23 ± 0.39 vs. LEs 20.66 ± 0.98; mean number of RGCs per
linear mm of retina, p = 0.040) (Fig. 4b and c), confirming the
neuroprotective effect of brimonidine during glaucoma.
Although it is generally accepted that glaucomatous
damage is a consequence of axonal degeneration that leads to
RGC death, glial activation is also present in glaucoma.61
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Experimental IOP triggers GFAP upregulation in astrocytes and
Müller cells.62 To test if the hypotensive effect of brimonidine
had any effect on GFAP expression in hypertensive eyes, GFAP
immunohistochemistry was performed in the radial eye sec-
tions of the [BRI-LAP] cohort. The results obtained showed
increased GFAP expression in the ganglion cell layer of the
central retina two weeks after injection of a hypertonic solu-
tion into the episcleral veins (Fig. 5). In contrast, there was not
an obvious increase in GFAP expression in the optic nerve
head of glaucomatous eyes (Fig. 5). No differences in GFAP
expression were observed between the glaucomatous eyes
injected with Bri-Lap (REs) and untreated control eyes (LEs)
(Fig. 5), suggesting that the Bri-Lap formulation does not have
a beneficial effect on the gliosis produced by the increased
IOP.
Concentration of brimonidine in rat eyes
In contrast to our previous study using dexamethasone release
in rabbits,40 this study on rats precluded analysis of the brimo-
nidine content in the different ocular tissues, and total
content in the rat eyes was determined after appropriate hom-
ogenization and subsequent fractionation by SPE. Fig. 6 shows
the brimonidine concentration curves vs. time over the course
of the study following IV administration of the Bri-Lap formu-
lation. Concentration is expressed in nanograms of brimoni-
dine per ml of the final solution.
Brimonidine concentration remains nearly constant in the
first week after IV administration (121.0 ± 25.6 ng ml−1),
showing a steady decrease until a plateau was reached at 6
weeks and achieving a value of 62.8 ± 9.0 ng ml−1 24 weeks
after administration. Brimonidine levels in contralateral eyes
were always below the detection limit.
4. Discussion
In our previous paper, we showed that the release of dexa-
methasone from LAPONITE® was sustained for up to
6 months in the vitreous body of healthy rabbit eyes.40 In this
Fig. 2 Functional examinations using electroretinography (ERG). (a) PhNR (photopic negative response) latency from the [BRI-LAP] cohort (rats
with ocular hypertension in both eyes and an intravitreal injection of brimonidine-LAPONITE® formulation in the right eye), maintained over 24
weeks. (b) PhNR amplitude, (a, b and PhNR waves) increased and was statistically significantly higher in eyes treated with the Bri-Lap formulation in
comparison with contralateral left eyes. (c) The scotopic ERG test showed lower (b wave) amplitude at 24 weeks in eyes treated with the Bri-Lap for-
mulation. (d) PhNR amplitude (a and PhNR waves) was statistically significantly higher in eyes treated with the Bri-Lap formulation in comparison
with hypertensive and untreated eyes in the [non-bri] cohort. Abbreviations: RE: right eye; LE: left eye; a wave: signal from photoreceptors; b wave:
signal from intermediate cells; PhNR wave: signal from retinal ganglion cells; Phases 1 to 7: multistep procedure with increasing intensity of lumi-
nance and different intervals from 0.0003 cds m−2 to 3.0 cds m−2; w: week; ms: milliseconds; μV: microvolts; *p < 0.05: statistical differences, **p <
0.001: statistical differences with Bonferroni’s correction.
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study, we decided to make three important changes: (1) use of
brimonidine, a different drug, to demonstrate the generality of
the release method; (2) tests in another animal (rats), required
before translational trials; and (3) application in a disease
model (chronic glaucoma) in order to confirm not only the
absence of side effects but also the therapeutic effect over an
extended period, the goal being to use the treatment in future
glaucomatous patients.
At present, there is no effective intravitreal hypotensive and
neuroprotective treatment for glaucoma or other optic neuro-
pathies in daily ophthalmology practice. The results of this
study show that a single intravitreal injection of the Bri-Lap
formulation, producing sustained release of brimonidine from
the LAPONITE® carrier clay for at least 6 months, had a func-
tional and structural hypotensive and neuroprotective effect.
As it is administered intravitreally, this formulation would
ensure treatment compliance and satisfactory control of the
disease over extended periods of time, with administration
being necessary perhaps twice yearly.
This paper shows that the Bri-Lap formulation has a net
hypotensive effect (decrease of approximately 9 mmHg) when
injected into an eye with ocular hypertension (compared to an
untreated hypertensive cohort [non-bri]) lasting for 8 weeks.
This is twice the time described when using intravitreal nanos-
ponges.52 The greatest hypotensive effect was observed in the
early stages and coincided with the greatest release of brimoni-
dine (approximately 120–80 ng ml−1). It disappeared in later
stages when the release of brimonidine plateaued (approxi-
mately 60 ng ml−1).
Meanwhile, the fact that in the eye injected intravitreally
with the Bri-Lap formulation IOP did not increase until week
3 of the study suggesting that the volume (3 microlitres) did
not cause hypertensive iatrogenesis and that the greatest
hypotensive effect (14.96 ± 4.16 vs. 23.34 ± 3.53 mmHg)
occurs within the first two weeks of administration.
However, from week 3 onwards the REs injected with Bri-Lap
showed higher IOP than the contralateral hypertensive left
eyes (p < 0.05). This finding may be because of both the
variability described for the Morrison technique56 for hyper-
tensive induction (although all injections were administered
by the same experienced ophthalmologist) and the intrinsic
characteristics of the clay. LAPONITE® becomes hydrated
and expands in volume in aqueous media.29 However, the
brimonidine deposited on the surface produces a hydro-
phobic effect, which gradually dissipates as release occurs,
which would delay hydration and expansion until the surface
of the LAPONITE® recovers its hydrophilic characteristics,
which appears to occur from week 3 or 4 onwards.
Neuroretinal examinations using OCT technology showed
that Bri-Lap formulation enhanced structural protection in
axonal (up to week 6) and ganglion structures in intermediate
(weeks 6 and 8) and late (weeks 12 and 24) stages. These
results support the previous ones, in which the greater hypo-
tensive effect observed in the early stages of the study pro-
tected the axons from IOP-dependent damage while the sub-
sequently inferior concentrations of brimonidine (in the order
of nanograms) detected in the plateau stage later provided
neuroretinal protection by interacting with the retina’s adre-
nergic receptors.7,17
Our findings also showed a protective functional effect, as
explored with the PhNR ERG and mainly applicable to the
RGCs (greater amplitude at week 12) and the axons (main-
Fig. 3 Neuroretinal analysis using OCT. (a) OCT sectors with increased thickness in right eyes injected with Bri-Lap formulation as compared with
untreated left eyes. (b) OCT sectors with statistically significant increases in thickness in right eyes from the [BRI-LAP] cohort as compared with right
eyes from the [non-bri] cohort. Dark to light greyish sectors indicate OCT neuroretinal sectors exhibiting greater thicknesses with statistical signifi-
cance, from earlier to later stages, respectively. Abbreviations: GCL: ganglion cell layer; RNFL: retinal nerve fibre layer; RE: right eye; LE: left eye; w:
week; d: day; *p < 0.05: statistical differences. REs from the [non-bri] cohort received an ocular hypertensive injection by sclerosing the episcleral
veins. LEs from the [non-bri] cohort did not receive any treatment. REs from the [BRI-LAP] cohort received an ocular hypertensive injection by scler-
osing the episcleral veins plus an intravitreal injection with brimonidine-LAPONITE® formulation. LEs from the [BRI-LAP] cohort received an ocular
hypertensive injection by sclerosing the episcleral veins.
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tained latency). This suggests that the Bri-Lap formulation has
a mainly protective effect on the soma of the RGCs, which was
corroborated in the histological studies’ finding of a higher
RGC count using the specific Ac Brn3a. Kim et al.,51 also
reported a neuroprotective effect after intravitreal injection of
brimonidine-loaded nanoparticles that improved RGC survival
in an optic nerve crush model, though this did not last longer
than 14 days. The axonal protection provided by intravitreal
brimonidine, associated with better anterograde and retro-
grade transport, has also been demonstrated by other
groups.63,64
The Bri-Lap intravitreal formulation also has a protective
structural and functional effect on the retina in the early
stages of treatment (up to week 8; p < 0.05). This was main-
tained in photoreceptors under photopic stimulation (but not
under scotopic stimulation) in the later stages (week 24) (see
Fig. 3d). Similar results were reported by Ortín-Martínez
et al.,22 where topical brimonidine had a protective effect on
the cones, and by Yukita et al.,63 who observed conservation of
RGC function under photopic conditions but without effect on
the a and b waves of the scotopic ERG. Intraocular injection of
brimonidine has also been shown to preserve outer nuclear
layer thickness as measured by OCT65 and even to reduce geo-
graphic atrophy secondary to age-related macular degeneration
in a phase 2 study with a brimonidine drug delivery system.26
The difference found between the protective functional
effect on RGCs (observed throughout the study) relative to
photoreceptors with photopic stimulus (found at a later stage)
may be due to the time required for the formulation to pass
through the different layers of the retina and approach the
photoreceptors. For instance, week 12 was the earliest that
intraretinal Bri-Lap formulation was observed using OCT
imaging.
OCT studies of GCL thickness detected a smaller percen-
tage loss of thickness in the REs of the [BRI-LAP] cohort from
week 4 onwards (vs. LE). However, a higher number of RGCs
were counted from the start of the study, indicating that
BRI-LAP also had an early neuroprotective effect on the
injected eye. This finding seems to suggest underestimation of
the neuroprotective effect on the GCL as measured by OCT.
Before week 4, the left eyes of the [BRI-LAP] cohort exhibited
greater GCL thickness (as measured by OCT) but nonetheless
showed a lower number of RGCs (histological studies). This
may be due to the increase in the size of the soma prior to
ganglion death66 because, as in the case of other authors who
used the same glaucoma model,48,67,68 RGC death was
observed in the early stages of the study (before week 4).
Another thickness confusion factor may have been glial infil-
tration and activation.69 This was ruled out, however, as glial
activation with no statistically significant differences between
REs and LEs was detected in the [BRI-LAP] cohort (with
induced bilateral glaucoma). Another fact to consider is that
the astrocyte and Müller cell reaction (detected using GFAP)
occurred at a very early stage of the study (from week 2
onwards) in both OHT-induced eyes, even when IOP was on
average less than 20 mmHg. This shows that an upward fluctu-
ation in IOP (albeit in a range considered normotensive:
<20 mmHg) triggered a premature immune response resulting
in consequent cell death, as also described in ref. 70 and 71.
These analyses seem to suggest a possible error or deviation
with regard to considering—in the early stages of the disease
—greater GCL thickness, as measured by OCT, as indicative of
better condition or protection, and lesser thickness as neuro-
degeneration. This long-term longitudinal study has demon-
strated the dynamism, and therefore change in thickness, that
can be quantified by OCT. The authors of this study consider
that the results measured by OCT in the early stages should be
Fig. 4 Retinal ganglion cell analysis in glaucomatous eyes. (a) Retinal
ganglion cells were counted in radial sections of the eye along 2 mm of
a linear region of the retina, corresponding to four areas, two on each
side of the optic nerve head (ONH). (b) Two representative images of the
ganglion cell layer marked with anti-Brn3a corresponding to a right eye
(RE) and a left eye (LE) of the same animal. Arrows mark the positive
nuclei to Brn3a. (c) The mean number of retinal ganglion cells per linear
mm of retina was significantly higher in hypertensive eyes injected with
Bri-Lap formulation than in the untreated contralateral hypertensive
eyes (RE 23.00 ± 0.39 vs. LE 20.66 ± 0.98, p = 0.040). Abbreviations: RE:
right eye; LE: left eye; ILM: internal limiting membrane. Scale bars: (a)
22.72 µm, (b) 5.8 µm.
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considered as a whole and not from the simplistic assumption
of greater thickness/protection and lesser thickness/damage,
as other authors have shown in other inflammatory neurode-
generative diseases.72
Interestingly, starting treatment with the Bri-Lap formu-
lation in one eye could also control IOP in the contralateral
eye, even though brimonidine levels were below the detection
limit. In this regard, it was observed that when LEs from the
[BRI-LAP] cohort were compared with LEs from the [non-bri]
cohort the percentage of eyes with OHT was lower in the
[BRI-LAP] cohort. Even in the later stages of the study (week
24) OCT detected greater thicknesses in the untreated hyper-
tensive LE in the [BRI-LAP] cohort when compared with a
healthy normotensive eye (left eye of the [non-bri] cohort) that
undergoes the physiological process of ganglion death and is
affected by the harmful agents in its OHT-induced contralat-
eral eye.73 These optimal results may have been a consequence
of retrograde and anterograde contralateral substance dissemi-
nation via the visual pathway74–76 and of improvement of
axonal transport by brimonidine.77 In addition, brimonidine
may spread through the blood vessels. Communication and
propagation of molecules to the opposite eye affecting the
retina has also been suggested.78 As brimonidine in the blood
was not quantified in this study, neither of these routes can be
ruled out.
It is a remarkable hallmark that intravitreal injection of Bri-
Lap produces neuroprotection, even with higher IOP (p <
0.05), in the treated eye very soon after injection and over a
period of six months. Furthermore, to the best of our knowl-
edge, this paper is the first to demonstrate a neuroprotective
effect on the eye contralateral to the one treated, which even
shows an improvement in degeneration over time.
Brimonidine concentration in the vitreous of treated
patients stands at 185 nM.79 The amounts analysed in the rats
Fig. 5 Increased GFAP expression was observed in the ganglion cell layer of the central retina two weeks after injection of a hypertonic solution
into the episcleral veins (black arrows). The Bri-Lap formulation does not induce any obvious change in GFAP expression in the retina or in the optic
nerve head in glaucomatous eyes. 1: Optic nerve; 2: Central retina; 3: Central vessel of the retina; 4: Optic nerve head; 5: Retinal pigment epithelium;
6: Sclera; Arrows: central retina without overexpression of GFAP. Scale bars: 82.2 µm.
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in our study reveal an apparent concentration (considering a
vitreous volume of 20 µl) ranging from 4.1 µM (week 1) to
2.0 µM (week 24). The decrease in drug levels in the eye
throughout the study coincided with the degradation (smaller
aggregates over time) of the Bri-Lap formulation observed
using OCT (unpublished data). It is an order of magnitude
greater than the concentration observed in patients and three
orders of magnitude greater than that required for receptor
activation, since only 2 nM of alpha-2 agonists are required for
maximum receptor activation.16 This suggests that formu-
lations with lower doses could also be effective while incurring
lower risk of side effects.
Brimonidine, in neutral form, shows very low solubility in
the aqueous phase. This is one of the reasons why it is usually
administered in cationic form (as tartrate). The slow release of
Bri-Lap can therefore be explained by two factors: the low solu-
bility of brimonidine and the retention ability of LAPONITE®
due to hydrogen bonds and van der Waals interactions, as we
previously observed with dexamethasone.40,47 All brimonidine
content (associated or not associated with LAPONITE®) was
measured in the eye over the study. As mentioned in the intro-
duction, brimonidine has a short half-life (12 hours) and rapid
clearance in the eye.10 It is probable that at 6 months (60 ng
ml−1) most of the analysed brimonidine is associated with
LAPONITE®. The very low (unknown) quantity of non-associ-
ated brimonidine would not control IOP efficiently in the final
stages of the study. This observation concurs with previous
authors, showing an initially higher ocular hypopressure
effect52 that decreases later (up to 4 weeks).53 Drug resistance
cannot therefore be ruled out. However, up to the end of the
study it showed a neuroprotective effect (as found when using
nanoparticles51). In addition, the basicity of the Bri-Lap formu-
lation could counteract the acidosis of glaucoma80,81 and
enhance the benefits.
This study demonstrates that using LAPONITE® as a drug
carrier for intraocular delivery has several advantages. From a
chemical perspective, the Bri-Lap formulation is easy and
simple to prepare and drug release is not associated with
carrier degradation, unlike other drug delivery systems
(DDS).82 From a clinical perspective, the clear, thixotropic and
nanoscale gel formulation allows it to be injected into the vitr-
eous body through smaller-gauge needles, in contrast to Brimo
DDS®—which requires applicators26—or other devices and
implants.83 To the authors’ knowledge, this is the first in vivo
study of a brimonidine DDS that shows longer sustained
reduction of IOP53,84 and a neuroprotective effect, even in a
disease model in which degradation is assumed to occur more
rapidly.
Limitations and future studies
It should be mentioned that there was a striking and unex-
pected level of early death among the rats. This may have
resulted from both repetition of intraperitoneal anaesthesia
with dexmedetomidine (deaths decreased drastically or dis-
appeared in the later stages when anaesthetic interventions
were less frequent), and by the depressant effects of brimoni-
dine on the central nervous system. It may also have been due
to potentiation of the effects of both alpha-2 agonists simul-
taneously.3 Brimonidine is able to cross the blood–brain
barrier,4 and can cause sedation, bradycardia, hypotension
and subsequent death.
Based on all the above, the authors consider that blood ana-
lysis and future pharmacodynamic adjustment and scaling
studies would be advisable and necessary before exploring
potential transferability to clinical practice. It would also be
interesting to co-insert85 different agents in the clay carrier to
combat various neurodegenerative pathways using microcap-
sule systems as described by Arranz-Romera et al.86 Prieto
Fig. 6 Mean brimonidine concentrations in rat eyes after intravitreal administration of the Bri-Lap formulation.
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et al.40 demonstrated sustained release and tolerance of intra-
ocular dexamethasone with LAPONITE®; this powerful anti-
inflammatory drug could combat gliosis and even improve the
results achieved in this study, as it appears that the Bri-Lap for-
mulation has no effect on gliosis as there are no differences
between eyes or cohorts with respect to GFAP.
5. Conclusions
This paper presents, for the first time, a study in which intra-
ocular administration in a rat eye of a brimonidine-
LAPONITE® formulation was well tolerated and had an early
functional and structural hypotensive and neuroprotective
effect. It acted mainly on retinal ganglion cells and the sus-
tained-release mechanism enabled a single intravitreal injec-
tion to last for at least 6 months. The study presents a formu-
lation with potential for transfer to clinical treatment of glau-
coma79 and other optic neuropathies.
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